Review: Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease

2007 ◽  
Vol 1 (1) ◽  
pp. 25-33 ◽  
Author(s):  
Lynette B. Fernandes ◽  
Peter J. Henry ◽  
Roy G. Goldie
2013 ◽  
Vol 14 (S1) ◽  
Author(s):  
Constantinos Glynos ◽  
Dimitris Toumpanakis ◽  
Zongmin Zhou ◽  
Peter Brouckaert ◽  
Theodoros Vassilakopoulos ◽  
...  

2009 ◽  
Vol 116 (6) ◽  
pp. 493-495 ◽  
Author(s):  
Tamera J. Corte ◽  
Stephen J. Wort

COPD (chronic obstructive pulmonary disease) is a significant health concern as the fourth leading cause of morbidity and mortality in the U.S.A. Although the prevalence of PH (pulmonary hypertension) in COPD is unknown, its presence is a risk factor for mortality. In this comment, we consider the role of PH in COPD and its pathophysiology, with reference to ET-1 (endothelin-1) and cigarette smoke, as well as exercise and nocturnal hypoxia. We also explore potential mechanisms for the observed improvement in exercise tolerance following 6 months of pravastatin treatment in COPD patients with PH as reported by Lee and co-workers in the present issue of Clinical Science, including possible effects upon ET-1 and Rho kinase, or antioxidant effects, which may be particularly relevant in this group of mainly current smokers.


Sign in / Sign up

Export Citation Format

Share Document